Label‐free relative quantification of alpha‐2‐macroglobulin site‐specific core‐fucosylation in pancreatic cancer by LC‐MS/MS

We describe a label‐free relative quantification LC‐MS/MS method for core‐fucosylation in alpha‐2‐macroglobulin (A2MG) immunoprecipitated from human sera. The method utilizes endoglycosidase F partial deglycosylation to reduce glycosylation microheterogeneity, while retaining the innermost N‐acetylglucosamine (GlcNAc) and core fucose. Precursor ion peak areas of partially deglycosylated peptides were obtained and site‐specific core‐fucosylation ratios based on the peak areas of core‐fucosylated and nonfucosylated counterparts were calculated and evaluated for assay development. This assay was applied in a preliminary study of sera samples from normal controls and patients with pancreatic diseases, including pancreatic cancer and chronic pancreatitis. A2MG fucosylation levels at sites N396 and N1424 were found to decrease in both chronic pancreatitis and pancreatic cancer compared to normal controls. The two sites were identified by two peptides and their core‐fucosylation ratios were found to be internally consistent. This method provides a platform to quantify fucosylation levels and can be used to study site‐specific core‐fucosylation aberrations in other glycoproteins for other diseases.

[1]  W. Hancock,et al.  Technologies and strategies for glycoproteomics and glycomics and their application to clinical biomarker research. , 2011, Analytical methods : advancing methods and applications.

[2]  Michelle A. Anderson,et al.  Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. , 2011, Journal of proteome research.

[3]  Michelle A. Anderson,et al.  Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. , 2006, Journal of proteome research.

[4]  Raymond A. Dwek,et al.  Targeting glycosylation as a therapeutic approach , 2002, Nature Reviews Drug Discovery.

[5]  Hao Chi,et al.  A Strategy for Precise and Large Scale Identification of Core Fucosylated Glycoproteins*S , 2009, Molecular & Cellular Proteomics.

[6]  L. Drahos,et al.  High-performance liquid chromatography coupled to mass spectrometry methodology for analyzing site-specific N-glycosylation patterns. , 2012, Journal of chromatography. A.

[7]  M. Ruffin,et al.  An N-glycosylation Analysis of Human Alpha-2-Macroglobulin Using an Integrated Approach. , 2012, Journal of proteomics & bioinformatics.

[8]  Hongyang Wang,et al.  Development of a combined chemical and enzymatic approach for the mass spectrometric identification and quantification of aberrant N-glycosylation. , 2012, Journal of proteomics.

[9]  B. Adamczyk,et al.  Characterization of fibrinogen glycosylation and its importance for serum/plasma N-glycome analysis. , 2013, Journal of Proteome Research.

[10]  Rune Matthiesen,et al.  An enzymatic deglycosylation scheme enabling identification of core fucosylated N-glycans and O-glycosylation site mapping of human plasma proteins. , 2007, Journal of proteome research.

[11]  Károly Héberger,et al.  Mass spectrometric and linear discriminant analysis of N-glycans of human serum alpha-1-acid glycoprotein in cancer patients and healthy individuals. , 2008, Journal of proteomics.

[12]  H. Desaire.  Glycopeptide Analysis, Recent Developments and Applications* , 2013, Molecular & Cellular Proteomics.

[13]  W. Borth.  α2“Macroglobulin, a multifunctional binding protein with targeting characteristics , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Yue Fan,et al.  Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. , 2011, Glycobiology.

[15]  H. Halsall,et al.  LC/MS analysis of complex multiglycosylated human alpha(1)-acid glycoprotein as a model for developing identification and quantitation methods for intact glycopeptide analysis. , 2010, Analytical biochemistry.

[16]  J. Marth,et al.  Glycosylation in Cellular Mechanisms of Health and Disease , 2006, Cell.

[17]  K. Huse,et al.  Alpha2-macroglobulin inhibits the malignant properties of astrocytoma cells by impeding beta-catenin signaling. , 2010, Cancer research.

[18]  D. Simeone,et al.  N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. , 2007, Journal of proteome research.

[19]  Ruedi Aebersold,et al.  Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry , 2003, Nature Biotechnology.

[20]  W. Hancock,et al.  Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. , 2006, Clinical chemistry.

[21]  A. Guttman,et al.  Comparative core fucosylation analysis of some major therapeutic antibody N-glycans by direct infusion ESI-MS and CE-LIF detection. , 2013, Journal of separation science.

[22]  David M. Rocke,et al.  Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data , 2009, Bioinform..

[23]  Pan‐Chyr Yang,et al.  Development of an AlphaLISA assay to quantify serum core-fucosylated E-cadherin as a metastatic lung adenocarcinoma biomarker. , 2012, Journal of proteomics.

[24]  S. Satomura,et al.  AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[25]  Lei Zhang,et al.  Large-scale assignment of N-glycosylation sites using complementary enzymatic deglycosylation. , 2011, Talanta.

[26]  Y. Mechref,et al.  Assigning N-glycosylation sites of glycoproteins using LC/MSMS in conjunction with endo-M/exoglycosidase mixture. , 2010, Journal of proteome research.